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1. Introduction 
Bone marrow is a complex tissue containing hematopoietic cell progenitors and their 
progeny integrated within a connective-tissue network of mesenchymal-derived cells 
known as the stroma (1). The stroma cells, or Mesenchymal stem cells (MSCs), are multi-
potent progenitor cells that constitute a minute proportion of the bone marrow, represented 
as a rare population of cells that makes up 0.001 to 0.01% of the total nucleated cells. They  
represent 10-fold less abundance than the haematopoietic stem cells (2), which contributes to 
the organization of the microenvironment supporting the differentiation of hematopoietic 
cells (3). MSC are present in tissues of young, as well as, adult individuals (4, 5), including 
the adipose tissue, umbilical cord blood, amniotic fluid and even peripheral blood (1, 6-8). 
MSCs were characterized over thirty years ago as fibroblast-like cells with adhesive 
properties in culture (9, 10). The term MSC has become the predominant term in the 
literature since the early 90s (11), after which their research field has grown rapidly due to 
the promising therapeutic potential, resulting in an increased frequency of clinical trials in 
the new millennium at an explosive rate.  
As data accumulated, there was a need to establish a consensus on the proper definition 
of the MSCs. The International Society for Cellular Therapy has recommended the 
minimum criteria for defining multi-potent human MSCs (12, 13). The criteria included: 
(i) cells being adherent to plastic under standard culture conditions; (ii) MSC being 
positive for the expression of CD105, CD73 and CD90 and negative for expression of the 
haematopoietic cell surface markers CD34, CD45, CD11a, CD19 or CD79a, CD14 or CD11b 
and histocompatibility locus antigen (HLA)-DR; (iii) under a specific stimulus, MSC 
differentiate into osteocytes, adipocytes and chondrocytes in vitro. These criteria 
presented properties to purify MSC and to enable their expansion by several-fold in-vitro, 
without losing their differentiation capacity. When plated at low density, MSCs form 
small colonies, called colony-forming units of fibroblasts (CFU-f), and which correspond 
to the progenitors that can differentiate into one of the mesenchymal cell lineages (14, 15). 
It has been reported lately that MSCs are able to differentiate into both mesenchymal, as 
well as, non-mesenchymal cell lineages, such as adipocytes, osteoblasts, chondrocytes, 
tenocytes, skeletal myocytes, neurones and cells of the visceral mesoderm, both in vitro 
and in vivo (16, 17). 
www.intechopen.com
  
Stem Cells in Clinic and Research 
 
60
All cells have half-lives and their natural expiration must be matched by their replacement; 
MSCs, by proliferating and differentiating, can be the proposed source of these new 
replacement cells as characterized in their differentiation capacity. This replacement 
hypothesis mimics the known sequence of events involved in the turnover and maintenance 
of blood cells that are formed from haematopoietic stem cells (HSCs) (18). Unlike HSCs, 
MSCs can be culture-expanded ex vivo in up to 40 or 50 cell doublings without 
differentiation (19). A dramatic decrease in MSC per nucleated marrow cell can be observed 
when the results are grouped by decade, thus showing a 100-fold decrease from birth to old 
age. Being pericytes present in all vascularized tissues, the local availability of MSC 
decreases substantially as the vascular density decreases by one or two orders of magnitude 
with age (20). In recent years, the discovery of MSCs with properties similar, but not 
identical, to BM-MSCs has been demonstrated in the stromal fraction of the connective 
tissue from several organs, including adipose tissue, trabecular bone, derma, liver and 
muscle (21-24). It is important to note that the origin of MSCs might determine their fate and 
functional characteristics (25). Studies of human bone marrow have revealed that about one-
third of the MSC clones are able to acquire phenotypes of pre-adipocytes, osteocytes and 
chondrocytes (16). This is in concordance with data showing that 30% of the clones from 
bone marrow have been found to exhibit a trilineage differentiation potential, whereas the 
remainder display a bi-lineage (osteo-chondro) or uni-lineage (osteo) potential (26). 
Moreover, MSC populations derived from adipose tissue and derma present a 
heterogeneous differentiation potential; indeed, only 1.4% of single cells obtained from 
adipose-derived adult stem cell (ADAS) populations were tri-potent, the others being bi-
potent or unipotent (27).  
2. Effect of Mesenchymal Stem Cells on Immune cells 
Mesenchymal Stem Cells have been shown to possess immunomodulatory characteristics, as 
described through the inhibition of T-cell proliferation in vitro (28-30). These observations 
have triggered a huge interest in the immunomodulatory effects of MSCs. The in vitro 
studies have been complemented in vivo, where both confirmed the immunosuppressive 
effect of MSC. MSC activating stimuli in vitro, appears to include the secretion of cytokines 
and the interaction with other immune cells in the presence of proinflammatory cytokines 
(Fig 1) (31). Primarily, the in vivo effect has been originally shown in a baboon model, in 
which infusion of ex vivo–expanded matched donor or third-party MSCs delayed the time to 
rejection of histo-incompatible skin grafts (29). The delay indicated a potential role for MSC 
in the prevention and treatment of graft-versus-host disease (GVHD) in ASCT, in organ 
transplantation to prevent rejection, and in autoimmune disorders. Recently, MSCs were 
used to successfully treat a 9-year-old boy with severe treatment-resistant acute GVHD, 
further confirming the potent immunosuppressive effect in humans (32). The 
immunosuppressive potential has no immunologic restriction, whether the MSCs are 
autologous with the stimulatory or the responder lymphocytes or the MSCs are derived 
from a third party. The degree of MSC suppression is dose dependent, where high doses of 
MSC are inhibitory, whereas low doses enhance lymphocyte proliferation in MLCs (33). 
Broadly, MSC modulate cytokine production by the dendritic and T cell subsets DC/Th1 
and DC/Th2 (34), block the antigen presenting cell (APC) maturation and activation (35), 
and increase the proportion of CD4+CD25+ regulatory cells in a mixed lymphocyte reaction 
(36).  
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Fig. 1. Potential mechanisms of the MSC interactions with immune cells. Mesenchymal 
stem cells (MSCs) can inhibit both the proliferation and cytotoxicity of resting natural killer 
(NK) cells, as well as, their cytokine production by releasing prostaglandin E2 (PGE2), 
indoleamine 2,3-dioxygenase (IDO) and soluble HLA-G5 (sHLA-G5). Killing of MSCs by 
cytokine-activated NK cells involves the engagement of cell-surface receptors (Thick blue 
line) expressed by NK cells with its ligands expressed on MSCs. MSCs inhibit the 
differentiation of monocytes to immature myeloid dendritic cells (DCs), bias mature DCs to 
an immature DC state, inhibit tumour-necrosis factor (TNF) production by DCs and increase 
interleukin-10 (IL-10) production by plasmacytoid DCs (pDCs). MSC-derived PGE2 is 
involved in all of these effects. Immature DCs are susceptible to activated NK cell-mediated 
lysis. MSC Direct inhibition of CD4+ T-cell function depends on their release of several 
soluble molecules, including PGE2, IDO, transforming growth factor-ǃ1 (TGFǃ1), 
hepatocyte growth factor (HGF), inducible nitric-oxide synthase (iNOS) and haem-
oxygenase-1 (HO1). MSC inhibition of CD8+ T-cell cytotoxicity and the differentiation of 
regulatory T cells mediated directly by MSCs are related to the release of sHLA-G5 by 
MSCs. In addition, the upregulation of IL-10 production by pDCs results in the increased 
generation of regulatory T cells through an indirect mechanism. MSC-driven inhibition of B-
cell function seems to depend on soluble factors and cell–cell contact. Finally, MSCs dampen 
the respiratory burst and delay the spontaneous apoptosis of neutrophils by constitutively 
releasing IL-6. 
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3. Immunomodulatory effect of mesenchymal stem cells in innate immunity 
Dendritic cells have the elementary role of antigen presentation to naïve T cells upon 
maturation, which in turn induce the proinflammatory cytokines. Immature DCs acquire the 
expression of co-stimulatory molecules and upregulate expression of MHC-I and II, as well 
as, other cell-surface markers (CD11c and CD83). Mesenchymal stem cells have profound 
effect on the development of DC, where in the presence of MSC, the percentage of DC with 
conventional phenotype is reduced, while that of plasmacytoid DC is increased, therefore 
biasing the immune system toward Th2 and away from Th1 responses in a PGE-2 
dependent mechanism (37). Furthermore, MSCs inhibit the up-regulation of CD1a, CD40, 
CD80, CD86, and HLA-DR during DC differentiation and prevent an increase of CD40, 
CD86, and CD83 expression during DC maturation (38). When mature DCs are incubated 
with MSCs they have a decreased cell-surface expression of MHC class II molecules, CD11c, 
CD83 and co-stimulatory molecules, as well as, decreased interleukin-12 (Il-12) production, 
thereby impairing the antigen-presenting function of the DCs (Fig 1) (39, 40). MSCs can also 
decrease the pro-inflammatory potential of DCs by inhibiting their production of tumour-
necrosis factor ǂ (TNF-ǂ) (40). Furthermore, plasmacytoid DCs (pDCs), which are 
specialized cells for the production of high levels of type-I IFN in response to microbial 
stimuli, upregulate production of the anti-inflammatory cytokine IL-10 after incubation with 
MSCs (34). These observations indicate a potent anti-inflammatory and immunoregulatory 
effect for MSC in vitro and potentially in vivo. 
Natural killer (NK) cells are key effector cells of the innate immunity in anti-viral and anti-
tumor immune responses through their Granzyme B mediated cytotoxicity and the 
production of pro-inflammatory cytokines (41). NK-mediated target cell lysis results from 
an antigen-ligand interaction realized by activating NK-cell receptors, and associated with 
reduced or absent MHC-I expression by the target cell (42). MSCs can inhibit the cytotoxic 
activity of resting NK cells by down-regulating expression of NKp30 and natural-killer 
group 2, member D (NKG2D), which are activating receptors involved in NK-cell activation 
and target-cell killing (Fig 1) (43). Resting NK cells proliferate and acquire strong cytotoxic 
activity when cultured with IL-2 or IL-15, but when incubated with MSC in the presence of 
these cytokines, resting NK-cell, as well as, pre-activated NK cell proliferation and IFN-Ǆ 
production are almost completely abrogated (44, 45). It is worth noting that although the 
susceptibility of NK cells to MSC mediated inhibition is potent, the pre-activated NK cells 
showed more resistance to the immunosuppressive effect of MSC compared to resting NK 
cells (43). The susceptibility of human MSCs to NK-cell-mediated cytotoxicity depends on 
the low level of cell-surface expression of MHC class I molecules by MSCs and the 
expression of several ligands, that are recognized by activating NK-cell receptors. 
Autologous and allogeneic MSC were susceptible to lysis by NK cells (43), where NK cell-
mediated lysis was inversely correlated with the expression of HLA class I on MSC (46). 
Incubation of MSCs with IFN-Ǆ partially protected them from NK-cell-mediated 
cytotoxicity, through the up-regulation of expression of MHC-I molecules on MSCs (43). 
Taken together, a possible dynamic interaction between NK cells and MSC in vivo exists, 
where the latter partially inhibit activated MSC, without compromising their ability to kill 
MSC, reflecting on an interaction tightly regulated by IFN-Ǆ concentration. 
Neutrophils play a major role in innate immunity during the course of bacterial infections, 
where they are activated to kill foreign infectious agents and accordingly undergo a 
respiratory burst. MSCs have been shown to dampen the respiratory burst and to delay the 
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spontaneous apoptosis of resting and activated neutrophils through an IL-6-dependent 
mechanism (47). MSC had no effect on neutrophil phagocytosis, expression of adhesion 
molecules, and chemotaxis in response to IL-8, f-MLP, or C5a (47). Stimulation with bacterial 
endotoxin induces chemokine receptor expression and mobility of MSCs, which secrete 
large amounts of inflammatory cytokines and recruit neutrophils in an IL-8 and MIF-
dependent manner. Recruited and activated neutrophils showed a prolonged lifespan, an 
increased expression of inflammatory chemokines, and an enhanced responsiveness toward 
subsequent challenge with LPS, which suggest a role for MSCs in the early phases of 
pathogen challenge, when classical immune cells have not been recruited yet (48). 
Furthermore, MSC have shown the capability to mediate the preservation of resting 
neutrophils, a phenomenon that might be important in those anatomical sites, where large 
numbers of mature and functional neutrophils are stored, such as the bone marrow and 
lungs (49). 
4. Immunomodulatory effect of mesenchymal stem cells in adaptive immunity 
T-cells are major players of the adaptive immune response. After T-cell receptor (TCR) 
engagement, T cells proliferate and undergo numerous effector functions, including 
cytokine release and, in the case of CD8+ T cells (CTL), cytotoxicity. Abundant reports have 
shown that T-cell proliferation stimulated with polyclonal mitogens, allogeneic cells or 
specific antigen is inhibited by MSCs (28, 29, 50-56). The observation that MSCs can reduce T 
cell proliferation in vitro is mirrored by the in vivo finding through infusions of hMSCs that 
control GVHD following bone marrow transplantation. Nevertheless, there is no 
demonstrable correlation between the measured effects of MSCs in vitro and their counter 
effect in vivo due to the lack of universality of methodology correlating the in vitro findings 
with the in vivo therapeutic potential.  
MSC inhibition of T-cell proliferation is not MHC restricted, since it can be mediated by both 
autologous and allogeneic MSCs and depends on the arrest of T-cells in the G0/G1 phase of 
the cell cycle (55, 57). Thus, MSCs do not promote T-cell apoptosis, but instead maintain T 
cell survival upon subjection to overstimulation through the TCR and upon commitment to 
undergo CD95–CD95-ligand-dependent activation-induced cell death (57). MSC effects on T 
cell proliferation in vitro appear to have both contact-dependent and contact-independent 
components (58). Inhibition of T-cell proliferation by MSCs leads to decreased IFN-Ǆ 
secretion in vitro and in vivo associated with increased IL-4 production by T helper 2 (TH2) 
cells (34, 59). Taken together, there is an implication for a shift from a pro-inflammatory 
state characterized by IFN-Ǆ secretion to an anti-inflammatory state characterized by IL-4 
secretion (Fig 1). An imperative role for effector T-cell is the MHC restricted killing of 
virally-infected or of allogeneic cells mediated via CD8+ CTLs, and which is down-regulated 
by MSC (60).  
Regulatory T cells (Tregs), a subpopulation of T cells, are vital to keep the immune system in 
check, help avoid immune-mediated pathology and contain unrestricted expansion of 
effector T-cell populations, which results in maintaining homeostasis and tolerance to self 
antigens. Tregs are currently identified by co-expression of CD4 and CD25, expression of the 
transcription factor FoxP3, production of regulatory cytokines IL-10 and TGF-ǃ, and ability 
to suppress proliferation of activated CD4+CD25+ T cells in co-culture experiments. 
Differential expression of CD127 (ǂ-chain of the IL-7 receptor) enable flow cytometry-based 
separation of human Tregs from CD127+ non-regulatory T-cells (61). MSCs have been 
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reported to induce the production of IL-10 by pDCs, which, in turn, trigger the generation of 
regulatory T cells (Fig 1) (34, 40). Furthermore, Tregs secrete TGF-ǃ and when used in vitro, 
TGF-ǃ in combination with IL-2 directs the differentiation of T-cells into Tregs, while Tregs 
suppress the proliferation of TCR-dependent proliferation of effector CD25null or CD25low T-
cells in a non-autologous fashion. Also TGF-ǃ alters angiogenesis following injury in 
experiments using MSC (62). In addition, after co-culture with antigen-specific T-cells, MSCs 
can directly induce the proliferation of regulatory T-cells through release of the 
immunomodulatory HLA-G isoform HLA-G5 (Fig 1) (63). Taken together, MSCs can 
modulate the intensity of an immune response by inhibiting antigen-specific T-cell 
proliferation and cytotoxicity and promoting the generation of regulatory T-cells.  
Antibody producing B-cells constitute the second main cell type involved in adaptive 
immunity. Interactions between MSCs and B-cells have produced controversial results 
attributable to the inconsistent experimental conditions used (31, 55, 64). Initial reports on 
mice suggested that MSC exercise a dampening effect on the proliferation of B-cells (64), 
which is in concordance with most published works to date (31, 55, 64). Furthermore, MSCs 
can also inhibit B-cell differentiation and constitutive expression of chemokine receptors via 
the release of soluble factors and cell-cell contact mediated possibly by the Programmed Cell 
Death 1 (PD-1) and its ligand (31, 64). The addition of MSCs, at the beginning of a mixed 
lymphocyte reaction (MLC), considerably inhibited immunoglobulin production in 
standard MLC, irrespective of the MSC dose employed, which suggests that third-party 
MSC are able to suppress allo-specific antibody production, consequently, overcoming a 
positive cross-match in sensitized transplant recipients (65). However, other in vitro studies 
have shown that MSCs could support the survival, proliferation and differentiation to 
antibody-secreting cells of B-cells from normal individuals and from pediatric patients with 
systemic lupus erythematosus (66, 67). A major mechanism of B-cell suppression was hMSC 
production of soluble factors, as indicated by transwell experiments, where hMSCs inhibited 
B-cell differentiation shown as significant impairment of IgM, IgG, and IgA production. 
CXCR4, CXCR5, and CCR7 B-cell expression, as well as chemotaxis to CXCL12, the CXCR4 
ligand, and CXCL13, the CXCR5 ligand, were significantly down-regulated by hMSCs, 
suggesting that these cells affect chemotactic properties of B-cells (Fig 1). B-cell 
costimulatory molecule expression and cytokine production were unaffected by hMSCs (64). 
Regardless of the controversial in vitro effects, B-cell response is mainly a T-cell dependent 
mechanism, and thus its outcome is significantly influenced by the MSC-mediated 
inhibition of T-cell functions. More recently, Corcione et al have shown that systemic 
administration of MSCs to mice affected by experimental autoimmune encephalomyelitis 
(EAE), a prototypical disease mediated by self-reactive T cells, results in striking disease 
amelioration mediated by the induction of peripheral tolerance (52). In addition, it has been 
shown that tolerance induction by MSCs may occur also through the inhibition of dendritic-
cell maturation and function (34, 35), thus suggesting that activated T cells are not the only 
targets of MSCs. 
Low concentrations of IFN-Ǆ upregulate the expression of MHC-II molecules by MSCs, 
which indicates that they could act as antigen presenting cells (APCs) early in an immune 
response, when the level of IFN-Ǆ are low (68, 69). However, this process of MHC-II 
expression by MSCs, along with the potential APC characteristics, was reversed as IFN-Ǆ 
concentrations increased. These observations could suggest that MSCs function as 
conditional APC in the early phase of an immune response, while later switch into an 
immunosuppressive function (68). Since bone marrow might be a site for the induction of T-
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cell responses to blood-borne antigens (70), and since MSC are derived from the stromal 
progenitor cells that reside in the bone marrow, therefore, MSC express a yet unidentified 
role in the control of the immune response physiology of the bone marrow. Dendritic cells 
are the main APC for T-cell responses, and MSC-mediated suppression of DC maturation 
would prohibit efficient antigen presentation and thus, the clonal expansion of T-cells. 
Direct interactions of MSCs with T-cells in vivo could lead to the arrest of T-cell proliferation, 
inhibition of CTL-mediated cytotoxicity and generation of CD4+ regulatory T-cells. As a 
consequence, impaired CD4+ T-cell activation would translate into defective T-cell help for 
B-cell proliferation and differentiation to antibody-secreting cells. 
The hMSCs express few to none of the B7-1/B7-2 (CD80/CD86) costimulatory–type 
molecules; this appears to contribute, at least in part, to their immune privilege 
characteristic. Mechanisms that lead to immune tolerance rely on interrelated pathways that 
involve complex cross talk and cross regulation of T-cells and APCs by one another. Both 
soluble mediators and modulation exerted via complex networks of cytokines and 
costimulatory molecules appear to play a role in MSC regulation of T cells, and these 
mechanisms invoke both contact-dependent and -independent pathways. 
Although many of the studies use MSC-conditioned medium, both contact-dependent and -
independent mechanisms are probably invoked in the therapeutic use of MSCs (20, 71). In 
addition to cytokines, the network of costimulatory molecules is hypothesized to play a 
prominent role in modulating tolerance and inflammation. MSCs down-regulate the 
expression of costimulatory molecules (30, 72, 73). The discovery of new functions for B7 
family members, together with the identification of additional B7 and CD28 family 
members, is revealing new ways in which the B7:CD28 family may regulate T-cell activation 
and tolerance. Not only do CD80/86:CD28 interactions promote initial T-cell activation, they 
also regulate self-tolerance by supporting CD4+CD25+ Treg homeostasis (74-76). Cytotoxic 
T-lymphocyte antigen 4 (CTLA-4) can exert inhibitory effects in both B7-1/B7-2–dependent 
and –independent fashions. B7-1 and B7-2 can signal bi-directionally through engaging 
CD28 and CTLA-4 on T cells and by delivering signals into B7-expressing cells (77). The B7 
family members—inducible co-stimulator (ICOS) ligand, PD-L1 (B7-H1), PD-L2 (B7-DC), 
B7-H3, and B7-H4 (B7x/B7-S1)—are expressed on professional APC cells, while B7-H4 and 
B7-H1 are expressed on hMSCs and on cells within non-lymphoid organs. These 
observations may provide a new means for regulating T-cell activation and tolerance in 
peripheral tissues (31, 71, 78). ICOS and PD-1 are expressed upon T-cell-induction, and they 
regulate previously activated T-cells (79). Both the ICOS:ICOSL pathway and the PD-1:PD-
L1/PD-L2 pathway play a critical role in regulating T-cell activation and tolerance (79). 
There is consensus that both CTLA-4 and PD-1 inhibit T-cell and B-cell activation and may 
play a crucial role in peripheral tolerance (79, 80). Both CTLA-4 and PD-1 functions are 
associated with Rheumatoid Arthritis (RA) and other autoimmune diseases. PD-1 is over 
expressed on CD4+ T cells in the synovial fluid of RA patients (81). Whether or not these 
costimulatory molecules are critical mediators of MSC-mediated immune suppression 
and/or tolerance in vivo is still under current investigation. 
5. Mesenchymal Stem Cells escape the immune system in vitro 
Studies have shown that MSCs escape the immune system, and this makes them a 
potential therapeutic tool for various transplantation procedures. MSCs express 
intermediate levels of HLA major histocompatibility complex (MHC) class I molecules 
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(16, 50, 82, 83), while they do not express HLA class II antigens of the cell surface. 
However, HLA class II is readily detectable by Western blot on whole-cell lysates of 
unstimulated adult MSCs, thus suggesting that MSCs contain intracellular deposits of 
HLA class II allo-antigens (83). Cell-surface expression can be induced by treatment of the 
cells with IFN-Ǆ for 1 or 2 days. Unlike adult MSCs, the fetal liver– derived cells have no 
intracellular nor cell surface HLA class II expression (84), but incubation with IFN-Ǆ 
initiated their intracellular expression followed by surface expression. Differentiation of 
MSCs into their mesodermal lineages of bone, cartilage, or adipose tissue, both in adult 
and fetal MSCs continued to express HLA-I, but not class II (84). Undifferentiated MSCs 
in vitro fail to elicit a proliferative response from allogeneic lymphocytes, thus suggesting 
that the cells are not inherently immunogenic (28, 30, 50). When pre-cultured with IFN-Ǆ 
for full HLA class II expression, MSCs still escape recognition by allo-reactive T-cells, (83, 
84) as is the case with MSCs differentiated adipocytes, osteoblasts, and chondrocytes. 
Limited in vivo data demonstrate the persistence of allogeneic MSCs into 
immunocompetent hosts after transplantation. In one patient treated with MSCs, DNA of 
donor MSC could not be detected in any organ at autopsy few weeks after the infusion, 
while in another patient receiving MSCs from two donors, the donor DNA from both 
donors was detected in lymph node and colon, the target organs of GVHD, within weeks 
after infusion (85). Data from our lab indicated that MSC were undetectable after two 
weeks in an allogeneic system (86). Therefore, the question of whether MSCs are 
recognized by an intact allogeneic immune system in vivo remains open, although the in 
vitro data support the theory that MSCs escape the immune system. MSCs do not express 
FAS ligand or costimulatory molecules, such as B7-1, B7-2, CD40, or CD40L (50). When 
costimulation is inadequate, T-cell proliferation can be induced by the addition of 
exogenous costimulation. However, MSCs differ from other cell types, and no T-cell 
proliferation can be observed when they are cultured with HLA-mismatched lymphocytes 
in the presence of a CD28-stimulating antibody (50). However, in agreement with the in 
vitro data, infusion or implantation of allogeneic and MHC-mismatched MSCs into 
baboons has been well tolerated (87-89). Unique immunologic properties of MSCs were 
also suggested by the fact that engraftment of human MSCs occurred after intra-uterine 
transplantation into sheep, even when the transplantation was performed after the fetuses 
became immunocompetent (90). MSC mainly fail to activate T-cells and show to be targets 
for CD8+ T cell-cytotoxicity, althought controversial (60). Phyto-hemagglutinin (PHA) 
blasts, generated to react against a specific donor, will lyse chromium-labeled 
mononuclear cells from that individual but it will not lyse MSCs derived from the same 
donor. Furthermore, killer cell inhibitory receptor (KIR ligand)–mismatched natural killer 
cells do not lyse MSCs (60). Thus, MSCs, although incompatible at the MHC, tend to 
escape the immune system. 
Although MSCs are transplantable across allogeneic barriers, a delayed type 
hypersensitivity reaction can lead to rejection in xenogenic models of human MSCs injected 
into immunocompetent rats (91). In this study, MSCs were identified in the heart muscle of 
severe compromised immune deficiency rats, in contrast to that of immunocompetent rats. 
In the latter group, peripheral blood lymphocytes proliferated after re-stimulation with 
human MSCs in vitro, thus suggesting cellular immunization. Such a proliferative response 
in vitro has not been detected in humans treated with intravenous (IV) infusion of allogeneic 
MSCs (Le Blanc and Ringdén, unpublished data, 2004). 
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6. Mechanisms of immunosuppression by Mesenchymal Stem Cells 
Several studies have acknowledged the immunosuppressive activities of MSCs, but the 
underlying mechanisms are far from being fully characterized. The initial step in the 
interaction between MSCs and their target cells involves cell–cell contact mediated by 
adhesion molecules, in concordance with studies showing the dependence of T-cell 
proliferation on the engagement of PD-1 by its ligand (31). Several soluble 
immunosuppressive factors, either produced constitutively by MSCs or released following 
cross-talk with target cells have been reported, including nitric oxide and indoleamine 2,3-
dioxygenase (IDO), which are only released by MSC after IFN-Ǆ stimulation with target cells 
(92, 93), and thus not in a constitutive manner. IDO induces the depletion of tryptophan 
from the local environment, which is an essential amino acid for lymphocyte proliferation. 
MSC-derived IDO was reported as a requirement to inhibit the proliferation of IFN-Ǆ-
producing TH1 cells (92) and together with prostaglandin E2 (PGE-2) to block NK-cell 
activity (Fig 1) (44). In addition, IFN-Ǆ, alone or in combination with TNF-ǂ, IL-1ǂ or IL-1ǃ, 
stimulates the production of chemokines by mouse MSCs that attract T-cells and stimulate 
the production of inducible nitric-oxide synthase (iNOS), which in turn inhibits T-cell 
activation through the production of nitric oxide (56). It is worth noting that MSCs from 
IFN-Ǆ receptor (IFN-Ǆ-R1) deficient mice do not have immunosuppressive activity, which 
highlights the vital role of IFN-Ǆ in the immunosuppressive function of MSC (56). 
Additional soluble factors, such as transforming growth factor-ǃ1 (TGF-ǃ1), hepatocyte 
growth factor (HGF), IL-10, PGE-2, haem-oxygenase-1 (HO1), IL-6 and soluble HLA-G5, are 
constitutively produced by MSCs (28, 34, 51, 63, 94) or secreted in response to cytokines 
released by target cells upon interacting with MSC. TNF-ǂ and IFN-Ǆ have been shown to 
stimulate the production of PGE-2 by MSCs above constitutive level (34). Furthermore, IL-6 
was shown to dampen the respiratory burst and to delay the apoptosis of human 
neutrophils by inducing phosphorylation of the transcription factor signal transducer and 
activator of transcription 3 (47), and to inhibit the differentiation of bone-marrow progenitor 
cells into DCs (95).  
The failure to reverse suppression, when neutralizing antibodies against IL-10, TGF-ǃ and 
IGF were added to MLR reactions does point to the possibility that MSC may secrete as yet 
uncharacterized immunosuppressive factors (93). Galectin-1 and Galectin-3, newly 
characterized lectins, are constitutively expressed and secreted by human bone marrow 
MSC. Inhibition of galectin-1 and galectin-3 gene expression with small interfering RNAs 
abrogated the suppressive effect of MSC on allogeneic T-cells (Fig 1) (96). The restoration of 
T-cell proliferation in the presence of ǃ- lactose indicates that the carbohydrate-recognition 
domain of galectins is responsible for the immunosuppression of T-cells and highlights an 
extracellular mechanism of action for the MSC-secreted galectins. In this respect, the 
inhibition of T-cell proliferation could result from either direct effects of galectin-1 and 
galectin-3 on T cells and/or through a direct or an indirect on effect on dendritic cells (97).   
HLA-G5 represents another important molecule involved in MSC mediated regulation of 
the immune response, where its production has been shown to suppress T-cell proliferation, 
as well as NK-cell and T-cell cytotoxicity, while promoting the generation of Tregs (63, 98). 
HLA-G protein expression is constitutive and the level is not modified upon stimulation by 
allogeneic lymphocytes in MSC/MLR. HLA-G5 is detected on MSCs by real-time reverse-
phase polymerase chain reaction, immune-fluorescence, flow cytometry and enzyme-linked 
immunosorbent assay in the supernatant (99). Cell contact between MSCs and activated T-
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cells induces IL-10 production, which, in turn, stimulates the release of soluble HLA-G5 by 
MSCs (63).  It is worth nothing that none of these molecules have an exclusive role and that 
MSC-mediated immune-regulation is a redundant system that is mediated by several 
molecules. 
7. Mesenchymal Stem Cells in response to injury 
One important characteristic of hMSCs is their ability to suppress inflammation resulting 
from injury, as well as, resulting from allogeneic solid organ transplants, and autoimmune 
disease. Consistent with in vitro studies, murine allogeneic MSCs are effective cellular 
therapy models in the treatment of murine models of human disease (52, 100-102). Several 
studies have documented the substantial clinical improvements observed in animal models, 
when MSC were systemically introduced as a therapy in mouse models of multiple sclerosis 
(102, 103), inflammatory bowel disease (104-106), infarct, stroke, and other neurologic 
diseases (107, 108), as well as diabetes (109). These findings strongly suggest that xenogeneic 
hMSCs are not immunologically recognized by various immunocompetent mouse models of 
disease and are able to home to sites of inflammation. However, the mechanisms behind the 
immunosuppressive actions at the site of inflammation and its association with the homing 
activity have not yet been completely elucidated.  
Nitric Oxide (NO) mediate its effect partly through phosphorylation of Stat-5, which results 
in suppression of T- cell proliferation, partly through the inhibition of NO synthase or the 
inhibition of prostaglandin synthesis. This reveals the MSC-dependent effects on 
proliferation. Although indoleamine-2, 3-dioxygenase (IDO) has been hypothesized to be 
critical in mediating the effect of NO, neutralizing IDO by using a blocking antibody did not 
interfere with NO’s suppressive effects (93, 110).  
Within an in vivo setting, injury, inflammation, and/or foreign cells can lead to T-cell 
activation, which results in those T-cells producing proinflammatory cytokines including, 
but not limited to, TNF-ǂ, IFN-Ǆ, IL-1ǂ, and IL-1ǃ. Combinations of cytokines may also 
induce cell production of chemokines, some of which bind to CXCR3-R expressing cells 
(including T cells) that co-localize with MSCs. MSCs then produce NO, which inhibits Stat-5 
phosphorylation, thereby leading to cell-cycle arrest (and thus halting T cell proliferation) 
(Fig 1) (110). In addition, iNOS appears to be important in mouse MSC in vivo effects. MSCs 
from mice that lack iNOS (or IFN-ǄR1) are unable to suppress GVHD. In contrast to mouse 
MSCs that use NO in mediating their immune-suppressive effect, hMSCs and MSCs from 
non-human primates appear to mediate their immune-suppressive effects via IDO (56). 
There is some controversy about whether the effect of IDO results from local depletion of 
tryptophan, or from the accumulation of tryptophan metabolites (which is suggested by 
data showing that use of a tryptophan antagonist, 1-methyl-L tryptophan, restored allo-
reactivity that would otherwise have been suppressed by MSCs). In addition to its effect on 
the JAK-STAT pathway, NO may also influence mitogen activated protein kinase and 
nuclear factor κB, which would cause a reduction in the gene expression of proinflammatory 
cytokines. 
8. Mesenchymal Stem Cell clinical applications  
The clinical experience with and the safety of MSCs is of utmost interest for their wide 
therapeutic applications. The pioneering in vivo studies with MSC focused on the 
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engraftment facilitation for the haematopoietic stem cells (111). Further work also focused 
on the regenerative functions of MSC in terms of functional repair of damaged tissues (112). 
Hypoimmunogenicity of MSC provided a critical advantage in their use for clinical and 
therapeutic purposes in vitro (50), followed by pre-clinical studies (29) and reaching the 
human clinical studies (32) with the use of allogeneic donors. Allogeneic MSC have proved 
to be an option with major advantages in clinical use, since the use of autologous MSC is 
hindered by the limited time frame for clonal expansion and the costly in vitro proliferation. 
However, some sub-acute conditions, such as autoimmune diseases, might allow the use of 
autologous MSCs and their culture in vitro. It is worth noting that some reports have 
recently challenged the belief that allogeneic MSCs are poorly immunogenic (113, 114), 
indicating that in some cases an autologous MSC source could be advantageous. Recent 
reports have shown that MSCs from patients with autoimmune disease have a normal 
capability to support hematopoiesis,  (115) and to exercise immunomodulatory functions 
(116), and to show a normal phenotypic characteristics (117).  
The perspective role of adult stem cells in degenerative disease conditions, where there is 
progressive tissue damage and an inability to repair, possibly due to the depletion of stem 
cell populations or functional alteration, has been considered. In cases of osteoarthritis, a 
disease of the joints where there is progressive and irreversible loss of cartilage 
characterized by changes in the underlying bone, Murphy et al showed that the proliferative 
capacity of the MSC was substantially reduced, and this was independent of the harvest site 
from patients with end-stage OA undergoing joint replacement surgery (118). In this study 
the marrow samples were harvested both from the site of surgery (either the hip or the 
knee) and also from the iliac crest. These effects were apparently disease-related, and not 
age-related. However, the data suggest that susceptibility to OA and perhaps other 
degenerative diseases may be due to the reduced mobilization or proliferation of stem cells. 
In addition, successfully recruited cells may have a limited capacity to differentiate, leading 
to defective tissue repair. Alternatively, the altered stem cell activity may be in response to 
the elevated levels of inflammatory cytokines seen in OA, which was confirmed by several 
other investigators (119, 120). 
Similarly, the functional impairment of the anti-proliferative effect of MSCs derived from 
patients with aplastic anaemia (121) or multiple myeloma (122) might be resulting from an 
intrinsic abnormality in the microenvironment of the bone marrow, which is consistent with 
the possible use of autologous MSC for therapeutic purposes.  
With the knowledge of the homing capacity of MSC and their capacity to engraft into the 
recipient’s bone after systemic administration, MSCs have been utilized to treat children 
with severe osteogenesis imperfecta, leading to improved parameters of increased growth 
velocity and total body mineral content associated with fewer fractures (123). Systemic 
infusion of allogeneic MSCs also led to encouraging bone marrow recovery in patients with 
tumors following chemotherapy (123). The immunosuppressive effect of infused MSCs has 
been successfully shown in acute, severe graft-versus-host disease (GvHD) (32). The 
probable effect of MSC was the inhibition of donor T-cell reactivity to histocompatibility 
antigens of the recipient tissue. Currently, there is no successful therapy for steroid-
refractory acute GVHD. The possible role of MSCs in this context is therefore of potential 
interest. Le Blanc et al reported a case of grade IV acute GVHD of the gut and liver in a 
patient who had undergone ASCT with cells from an unrelated female donor (32). The 
patient was unresponsive to all types of immunosuppression drugs. When the patient was 
infused with 2x 106 MSCs per kilogram from his HLA-haploidentical mother, his GVHD 
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responded with a decline in bilirubin and normalization of stools. After the MSC infusion, 
DNA analysis of his bone marrow showed the presence of minimal residual disease (124). 
When immunosuppression was discontinued, the patient again developed severe acute 
GVHD, with its associated symptoms within a few weeks. 
Modulation of host allo-reactivity led to accelerated bone-marrow recovery in patients co-
transplanted with MSCs and haplo-identical HSCs (125). Clinical trials are being conducted 
on the immunomodulatory potential of MSCs in the treatment of Crohn’s disease, with the 
potential for those cells to contribute to the regeneration of gastrointestinal epithelial cells 
(126).   
As described previously, MSCs are characterized by their hypoimmunogenicity. In 2000, 
data from several research groups demonstrated long-term allo-MSC engraftment in a 
variety of non-cardiac tissues in the absence of immunosuppression (88, 90). On the basis of 
these observations, investigators began to look into the possibility of allo-MSCs engraftment 
into affected myocardium in rats, and later in swine, where allo-MSCs were found to readily 
engraft in necrotic myocardium and favorably alter ventricular function (2). The allo-MSC 
engraftment occurred without evidence of immunologic rejection or lymphocytic infiltration 
in the absence of assisted immunosuppressive therapy emphasizing some of the apparent 
advantages of these cells over other cell populations for cellular cardiomyoplasty. The 
immunologically privileged status of MSCs was also observed in xenogeneic setting, where 
Saito et al injected MSC intravenously from C57BL/6 mice into immunocompetent adult 
Lewis rats (127). When these animals were later subjected to MIs, murine MSCs could be 
identified in the region of necrosis, and these cells expressed muscle specific proteins not 
present before coronary ligation.  
9. Animal models 
Consistent with results from in vitro studies, murine allogeneic MSCs are effective in the 
treatment of murine models of human disease (52, 103, 128). Several studies have reported 
clinical improvements in mouse models of multiple sclerosis and amyotrophic lateral 
sclerosis, inflammatory bowel disease, stroke, diabetes, infarct and GVHD using I.V. 
injected xenogeneic hMSCs rather than allogeneic MSCs (108, 109). A major advantage in 
using hMSCs in mouse models of human disease is that the possibility of gathering 
mechanistic data through measuring biomarkers from body fluids or using noninvasive 
imaging technology, which may prove to be an advantage in clinical studies when applied 
on humans.  
In experiments designed to study the trafficking of hMSCs, investigators used mouse 
models of severe erosive polyarthritis characterized by an altered transgene allele that 
results in chronic over-expression of TNF-ǂ and which resemble human RA patients (60, 72).  
The motive behind utilizing these mice models was to investigate similarities in MSC 
homing with mouse models of chronic asthma and acute lung injury. Injected hMSC 
revealed a reduction in ankle arthritis parameters associated with decrease appendage 
related erythema, possibly due to the MSC localization to ankle joints as revealed by 
bioluminescence (129). Similar observations for inducing tolerance were made using 
adipose-derived MSC, where Treg were induced in RA PBMC and in mouse models of 
arthritis (36, 130). Furthermore, studies of rheumatoid arthritis T-cells showed a down-
regulation of effector response using adipose-derived MSCs (131). Variations in this 
potential described by the capability of MSCs to down-regulate collagen-induced arthritis, 
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and in the ability to induce Tregs, depend on the source of MSC (mouse vs. human) and its 
characteristics (primary isolate of MSC line), which reflect on difference in function 
compared to primary expanded MSC (132). Other studies reported that in the collagen-
induced model of arthritis, mice infused with MSCs have increased numbers of CD4+CD25+ 
cells that express FoxP3 and thus reveal a Treg phenotype (20). Recent data on collagen-
induced arthritis model, where murine MSCs did not reveal therapeutic benefits against 
arthritis in vivo, but did show anti-proliferative effect in vitro suggest that there is no 
appropriate in vitro measures that can be accurately extrapolated into a potential therapeutic 
utility of MSCs in vivo, and that mouse MSCs show difference in functional characteristics to 
hMSC in terms of immunoregulatory capacity (133).  
MSC’s immunological properties appeared to have potential therapeutic advantages in 
other forms of autoimmune diseases, especially in type 1 diabetes. In NOD mouse model, 
several physiological defects that aim to maintain peripheral and central tolerance 
contribute to the development of autoimmune diabetes. These defects are summed up as a 
combination of immune cell dysfunction (including T-cell, NK cells, B-cells, and dendritic 
cells), associated with the presence of inflammatory cytokine milieu (134). MSCs possess 
specific immunomodulatory properties capable of halting autoimmunity through 
immunomodulation processes described in this chapter. The processes might be through a 
direct effect via the presentation of differential levels of negative costimulatory molecules 
and the secretion of regulatory cytokines that affect regulatory T-cells/autoreactive T-cells. 
Furthermore, MSCs could modulate the immunological dysregulation observed in antibody 
producing B-cells and cytotoxic NK cells. Dendritic cells have been shown to be defective in 
NOD mice characterized by higher levels of costimulation with a potential capability to shift 
to a TH-1 type of immune response. 
In an experimental mouse model of diabetes induced by streptozotocin, it was observed that 
MSCs promoted the endogenous repair of pancreatic islets and renal glomeruli (109). 
Similarly, co-infusion of MSCs and bone-marrow cells inhibited the proliferation of ǃ-cell-
specific T-cells isolated from the pancreas of diabetic mice and restored insulin and glucose 
levels through the induction of recipient-derived pancreatic ǃ-cell regeneration in the 
absence of trans-differentiation of MSCs (135). These studies show that the in vivo 
administration of MSCs is clinically efficacious through the modulation of pathogenic ǃ- 
and T-cell responses and through potent bystander effects on the target tissue. 
The timing of MSC infusion seems to be a critical parameter in their therapeutic efficacy. In 
the EAE mouse model of multiple sclerosis, MSC systematically injected at disease onset 
ameliorated myelin oligodendrocyte glycoprotein (MOG)-induced EAE and further 
decreased the infiltration T-cells, B-cells and macrophages into the central nervous system 
(CNS). Furthermore, T cells isolated from the lymph nodes of MSC-treated mice did not 
proliferate after in vitro re-challenge with MOG peptide, which is an indication of the 
induction of T-cell anergy (52). Systematic injection of MSCs was found to inhibit the in vivo 
production of pathogenic plp-specific antibodies and to suppress the encephalitogenic 
potential of plp-specific T cells in passive-transfer experiments. In this model, the MSCs 
migrated to the lymphoid organs, as well as, to the inflamed CNS, where they exercised a 
protective effect on the neuronal axons in situ (135, 136). In these studies, the therapeutic 
effect of MSCs depended on the release of anti-apoptotic, anti-inflammatory and trophic 
molecules, as occurred in the case of stroke in rats (137), and, possibly, on the recruitment of 
local progenitors and their subsequent induction to differentiate into neural cells (138). As 
trophic effect, the MSCs appeared to favor oligo-dendrogenisis by neural precursor cells 
(139). 
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Several other studies have provided insights into the effects of MSCs mediated by cytokines. 
In a model of acute renal failure, the administration of MSCs increased the recovery of renal 
function through the inhibition of production of proinflammatory cytokines, such as Il-1ǃ, 
TNF and IFNǄ, and through an anti-apoptotic effect on target cells (140). Along the same 
line, the anti-inflammatory activity of MSCs was revealed in a mouse model of lung fibrosis, 
where they inhibited the effects of IL-1ǂ-producing T cells and TNF-producing 
macrophages through the release of IL-1 receptor antagonist (IL-1RA) (141). The release of 
trophic factors such as the WNT-associated molecule secreted frizzled-related protein 2 
(SFRp2), which leads to the rescue of ischemic cardiomyocytes and the restoration of 
ventricular functions represent another important function for MSC (142). 
With all the promising therapeutic potential of MSC, there seems to be a growing concern 
about their association with tumors. The immunoregulatory and anti-proliferative effects of 
MSCs led to several studies investigating the inhibitory effect of MSCs on tumor growth. 
Inhibition or, more frequently, stimulation of tumor-cell proliferation in vitro and/or tumor 
growth in vivo by MSCs has been reported (143-145). The heterogeneous nature of the MSC 
populations and the different experimental tumor models used, contribute to the effect of 
tumors on MSC in which the microenvironment generated by tumors influence the behavior 
of MSCs (146). Two main mechanisms are probably involved in the enhancement of tumor 
growth by MSCs. First, the cell-to-cell cross-talk between MSCs and tumor cells contribute 
to tumor progression, thus integrating within the tumor stroma (147), and second, the 
suppressive effects of MSCs on the immune system of tumor-bearing hosts might facilitate 
tumorigenesis, as shown for the inhibition of melanoma rejection, possibly mediated by 
regulatory CD8+ T cells (144). Irrespective of the possible interactions between cancer cells, 
immune cells and MSCs, the potential risk of stimulating the growth cancer by MSCs must 
be considered. 
10. Conclusion 
As a whole, the data accumulated from preclinical and clinical data indicate that bone 
marrow-derived MSCs have, in addition to their therapeutic purposes in regenerative 
medicine, effects that can result from other characteristics, such as their anti-proliferative 
and anti-inflammatory properties. The immuno suppressive activity of MSCs provides 
means for inducing peripheral tolerance following systemic injection mediated through the 
inhibition of cell division, thereby preventing their responsiveness to antigenic triggers 
while maintaining them in a quiescent state. In addition, the clinical efficacy of MSCs in 
different experimental model seems to occur almost only during the acute phase of disease 
associated with limited trans-differentiation, which indicates that the therapeutic 
effectiveness of MSCs relies heavily on their ability to modify microenvironments. These 
modifications occur through the release of anti-inflammatory cytokines, and anti-apoptotic 
and trophic molecules that promote the repair and protection of damaged tissues, as well as, 
maintain the integrity of the immune cells.  
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considered to be untreatable. Remarkable achievements in cell biology resulting in the isolation and
characterization of various stem cells and progenitor cells has increased the expectation for the development
of a new approach to the treatment of genetic and developmental human diseases. Due to the fact that
currently stem cells and umbilical cord banks are so strictly defined and available, it seems that this mission is
investigationally more practical than in the past. On the other hand, studies performed on stem cells, targeting
their conversion into functionally mature tissue, are not necessarily seeking to result in the clinical application
of the differentiated cells; In fact, still one of the important goals of these studies is to get acquainted with the
natural process of development of mature cells from their immature progenitors during the embryonic period
onwards, which can produce valuable results as knowledge of the developmental processes during
embryogenesis. For example, the cellular and molecular mechanisms leading to mature and adult cells
developmental abnormalities are relatively unknown. This lack of understanding stems from the lack of a good
model system to study cell development and differentiation. Hence, the knowledge reached through these
studies can prove to be a breakthrough in preventing developmental disorders. Meanwhile, many researchers
conduct these studies to understand the molecular and cellular basis of cancer development. The fact that
cancer is one of the leading causes of death throughout the world, highlights the importance of these
researches in the fields of biology and medicine.
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